Literature DB >> 7199041

Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects.

E A Swabb, M A Leitz, F G Pilkiewicz, A A Sugerman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7199041     DOI： 10.1093/jac/8.suppl_e.131

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  32 in total

1.  Penetration of aztreonam into cerebrospinal fluid and brain of noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa.

Authors:  L J Strausbaugh; C R Bodem; P R Laun
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

2.  In vitro and in vivo studies of the effect of aztreonam on platelet function and coagulation in normal volunteers.

Authors:  T A Tartaglione; R J Duma; G D Qureshi
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  Distribution of ceftazidime in ascitic fluid.

Authors:  G Benoni; E Arosio; M G Raimondi; E Apolloni; E Passarella; A Lechi; G P Velo
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  Pharmacokinetics of aztreonam in elderly male volunteers.

Authors:  W A Creasey; T B Platt; M Frantz; A A Sugerman
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

5.  Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.

Authors:  Alexander A Vinks; Ronald N van Rossem; Ron A A Mathôt; Harry G M Heijerman; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

6.  The clinical relevance of plasma protein binding changes.

Authors:  Jason A Roberts; Federico Pea; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

7.  In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients.

Authors:  H R Stutman; D F Welch; R K Scribner; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

8.  Biliary excretion of aztreonam in patients with biliary tract disease.

Authors:  O V Martinez; J U Levi; R G Devlin
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of aztreonam. An update.

Authors:  H Mattie
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

10.  Evaluation of aztreonam in the treatment of severe bacterial infections.

Authors:  J Romero-Vivas; M Rodríguez-Créixems; E Bouza; T Hellín; A Guerrero; J Martínez-Beltrán; M García de la Torre
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.